Study: Smoking-cessation drug shows success in smaller doses

07/26/2006 | United Press International

Samoxen said a Phase II trial of its nalmefene hydrochloride oral smoking-cessation drug showed it led to higher abstinence rates in volunteers who received 40mg doses. But the firm also reported a less-successful rate among those receiving it in 80mg doses and said the trial was designed to be "exploratory in nature."

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI